IP Library › Granted Patent US 9,957,224
Granted Patent B2
US 9,957,224 · App. 13/887,243 · Granted May 1, 2018

Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Inventors: Claes Olof Bavik (Lake Forest Park, WA); Susan Hayes Henry (Kirkland, WA); Ryo Kubota (Seattle, WA); Vladimir A. Kuksa (Bothell, WA)
Assignee: ACUCELA INC
C07C215/08A61K31/137A61K31/138A61K31/35A61K31/765A61K45/06C07C211/27C07C217/20C07C323/32C07D309/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,957,224
App. No.
13/887,243
Granted
May 1, 2018
Kind
B2
Abstract

Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.

Claims (5)

1. A method for treating proliferative diabetic retinopathy in a patient having been previously diagnosed with proliferative diabetic retinopathy comprising administering to the patient a therapeutically effective amount of a composition comprising a compound, or stereoisomer, N-oxide or a pharmaceutically acceptable salt thereof, having the structure:

2. The method of claim 1 , wherein the composition is administered to the patient orally.

3. The method of claim 1 , wherein the composition is administered once per day, and the composition is administered in the evening or prior to going to sleep.

4. The method of claim 1 , wherein treatment results in improvement of central vision in the patient.

5. The method of claim 1 , 2 , 3 , or 4 , wherein the (R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol is administered as a daily dose of about 2 mg; about 5 mg; about 7 mg; or about 10 mg.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME: VLADIMIR A. KUKSA PREVIOUSLY RECORDED ON REEL 031733 FRAME 0892. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 17, 2013
From: BAVIK, CLAES OLOF; HENRY, SUSAN HAYES; KUBOTA, RYO; KUKSA, VLADIMIR A.
To: ACUCELA INC.
Reel/Frame 031867/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2013
From: BAVIK, CLAES OLOF; HENRY, SUSAN HAYES; KUBOTA, RYO; KUSKA, VLADIMIR A.
To: ACUCELA INC.
Reel/Frame 031733/0892 →
Continuity (5)
Provisional Application 61643051 · May 4, 2012
Provisional Application 61643058 · May 4, 2012
Provisional Application 61643178 · May 4, 2012
Provisional Application 61781907 · Mar 14, 2013
Related Publication 20140039048A1 · Feb 6, 2014